Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.
4.

Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.

Teimouri F, Nikfar S, Abdollahi M.

Melanoma Res. 2013 Oct;23(5):381-9. doi: 10.1097/CMR.0b013e3283649a97. Review.

PMID:
23880781
5.

Management of metastatic cutaneous melanoma.

Buzaid AC.

Oncology (Williston Park). 2004 Oct;18(11):1443-50; discussion 1457-9. Review.

6.

[Therapy of malignant melanoma at the stage of distant metastasis].

Garbe C, Eigentler TK.

Hautarzt. 2004 Feb;55(2):195-213. Review. German.

PMID:
15043023
7.

Temozolomide for Treating Malignant Melanoma.

Li RH, Hou XY, Yang CS, Liu WL, Tang JQ, Liu YQ, Jiang G.

J Coll Physicians Surg Pak. 2015 Sep;25(9):680-8. doi: 09.2015/JCPSP.680688. Review.

PMID:
26374366
8.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA.

J Clin Oncol. 1999 Jul;17(7):2105-16. Review.

PMID:
10561265
9.

High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.

Marabondo S, Kaufman HL.

Expert Opin Drug Saf. 2017 Dec;16(12):1347-1357. doi: 10.1080/14740338.2017.1382472. Epub 2017 Sep 21. Review.

PMID:
28929820
10.

Metastatic melanoma: chemotherapy to biochemotherapy.

O'Day SJ, Kim CJ, Reintgen DS.

Cancer Control. 2002 Jan-Feb;9(1):31-8. Review.

PMID:
11907464
11.

Temozolomide-related infections: review of the literature.

Kizilarslanoglu MC, Aksoy S, Yildirim NO, Ararat E, Sahin I, Altundag K.

J BUON. 2011 Jul-Sep;16(3):547-50. Review.

PMID:
22006764
12.

Intralesional immunotherapy as a strategy to treat melanoma.

Nouri N, Garbe C.

Expert Opin Biol Ther. 2016;16(5):619-26. doi: 10.1517/14712598.2016.1157161. Epub 2016 Mar 9. Review.

PMID:
26898656
13.
14.

Immunotherapy of melanoma.

Haanen JB.

EJC Suppl. 2013 Sep;11(2):97-105. doi: 10.1016/j.ejcsup.2013.07.013. Review.

15.

Update on use of aldesleukin for treatment of high-risk metastatic melanoma.

Amaria RN, Reuben A, Cooper ZA, Wargo JA.

Immunotargets Ther. 2015 Apr 7;4:79-89. doi: 10.2147/ITT.S61590. eCollection 2015. Review.

16.

Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses.

De La Torre K, Cohen E, Loeser A, Hurlbert M; Metastatic Breast Cancer Alliance.

NPJ Breast Cancer. 2017 Mar 16;3:7. doi: 10.1038/s41523-017-0010-1. eCollection 2017. Review.

Supplemental Content

Support Center